Faculty Information - Takayuki Iwamoto

（Last updated : 2024-04-10 16:12:40）

Takayuki Iwamoto
Department Kawasaki Medical School Kawasaki Medical School, Department of Breast and Thyroid Surgery,

Position Assistant Professor

■ Journal

1.	2023/11	An observational study of the impact of immediate breast reconstruction on perioperative inflammatory cytokines.
2.	2023/09	Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer.
3.	2023/06	Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
4.	2023/06	Impact of Immediate Breast Reconstruction on Survival of Breast Cancer Patients: A Single-Center Observational Study.
5.	2023/03	Correction: Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.
6.	2023/01	Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.
7.	2023/01	Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery.
8.	2022/11	Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.
9.	2022/10	Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials.
10.	2022/08	Gene Expression Profiling between Patient Groups with High and Low Ki67 Levels after Short-term Preoperative Aromatase Inhibitor Treatment for Breast Cancer
11.	2022/05	Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression.
12.	2021/11	YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
13.	2021/10	A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study.
14.	2021/08	Differences in Attitudes and Practices of Cancer Pain Management between Medical Oncologists and Palliative Care Physicians
15.	2021/08	Differences in Attitudes and Practices of Cancer Pain Management between Medical Oncologists and Palliative Care Physicians.
16.	2021/04	A Multicenter Study of Docetaxel at a Dose of 100 mg/m2 in Japanese Patients with Advanced or Recurrent Breast Cancer.
17.	2021/03	Relationships of physical and breast cancer phenotypes with three single-nucleotide polymorphisms (rs2046210, rs3757318, and rs3803662) associated with breast cancer risk in Japanese women.
18.	2021/03	Simultaneous hot and cold thyroid nodules: Which is malignant?
19.	2021/01	Effect of isoflavones on breast cancer cell development and their impact on breast cancer treatments.
20.	2020/11	Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study.
21.	2020/10	Evaluation of Prognosis of Juvenile Differentiated Thyroid Carcinoma.
22.	2020/09	The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs.
23.	2020/07	Influences of preoperative metformin on immunological factors in early breast cancer.
24.	2020/07	NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy.
25.	2020/06	Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer.
26.	2020/04	Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
27.	2020/03	Influence of breast density on breast cancer risk: a case control study in Japanese women.
28.	2020/01	Recurring radiation-induced angiosarcoma of the breast that was treated with paclitaxel chemotherapy: a case report.
29.	2020/01	Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
30.	2019/09	Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples.
31.	2019/09	Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
32.	2019/08	Role of Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Study from the Japanese Breast Cancer Registry.
33.	2018/11	Comparison of Ki-67 labeling index measurements using digital image analysis and scoring by pathologists.
34.	2018/08	Hormonal Therapy Resistant Estrogen-receptor Positive Metastatic Breast Cancer Cohort (HORSE-BC) Study : Current Status of Treatment Selection in Japan.
35.	2018/06	Advance care planning in metastatic breast cancer.
36.	2018/06	CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer.
37.	2018/04	Current Multidisciplinary Approach to Fertility Preservation for Breast Cancer Patients.
38.	2018/01	Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
39.	2017/04	Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.
40.	2017/03	Development of a Japanese version of the BREAST-Q and the traditional psychometric test of the mastectomy module for the assessment of HRQOL and patient satisfaction following breast surgery.
41.	2017	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status.
42.	2016/12	Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.
43.	2016/11	Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry.
44.	2016/10	A Phase I Trial of 100 mg/m2 Docetaxel in Patients with Advanced or Recurrent Breast Cancer.
45.	2016/09	A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.
46.	2016/08	A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.
47.	2016/07	Diagnostic performance of (18)F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis.
48.	2016/06	Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry.
49.	2016/05	Evaluation of aldehyde dehydrogenase 1 and transcription factors in both primary breast cancer and axillary lymph node metastases as a prognostic factor.
50.	2016/04	Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry.
51.	2016/04	Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
52.	2016/01	Assessment of the Ki67 labeling index: a Japanese validation ring study.
53.	2016/01	Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004.
54.	2016/01	Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2005.
55.	2016/01	Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006.
56.	2016/01	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
57.	2015/10	A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ of the breast.
58.	2015	Correlation between 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography and Clinicopathological Features in Invasive Ductal Carcinoma of the Breast.
59.	2015	Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer: NACED-Randomized Multicenter Phase II Trial.
60.	2014/10	Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
61.	2014/05	TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.
62.	2014/01	Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
63.	2014	A case of carcinoma showing thymus-like differentiation with a rapidly lethal course.
64.	2013/12	Effects of lifestyle and single nucleotide polymorphisms on breast cancer risk: a case-control study in Japanese women.
65.	2013/11	Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.
66.	2013/11	TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.
67.	2013/09	Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.
68.	2013/04	A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.
69.	2013/01	Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment.
70.	2013	Association between mammographic breast density and lifestyle in Japanese women.
71.	2013	Bayesian mixture models for assessment of gene differential behaviour and prediction of pCR through the integration of copy number and gene expression data.
72.	2013	DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.
73.	2013	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
74.	2012/11	Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells.
75.	2012/08	Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer.
76.	2012/03	Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.
77.	2012/02	Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer.
78.	2012	Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.
79.	2012	Inflammatory breast cancer: what we know and what we need to learn.
80.	2011/12	Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems.
81.	2011/11	First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations.
82.	2011/08	Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.
83.	2011/04	Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.
84.	2011/02	Breast cancer prognostic markers in the post-genomic era.
85.	2011/02	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer.
86.	2011/02	Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
87.	2011	Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
88.	2011	Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.
89.	2010/11	Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?
90.	2010/11	Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
91.	2010/10	Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
92.	2010/09	Laparoscopic tailored Nissen fundoplication.
93.	2008/11	Preoperative assessment of the risk factors that help to predict the prognosis after living donor liver transplantation.
94.	2008/09	Effects of prophylactic splenic artery modulation on portal overperfusion and liver regeneration in small-for-size graft.
95.	2008/05	The impact of donor age on the outcome of adult living donor liver transplantation.
96.	2008/02	The outcome of living donor liver transplantation with prior spontaneous large portasystemic shunts.
97.	2007/11	Preoperative proximal splenic artery embolization: a safe and efficacious portal decompression technique that improves the outcome of live donor liver transplantation.
Display 5 items
Display all(97)